Compare Cytokinetics Inc (CYTK) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Medpace Holdings Inc — how do they compare? Cytokinetics Inc trades at $62.69 (market cap $8.62B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Medpace Holdings Inc for 14 Days on average.
| CYTK | MEDP | |
|---|---|---|
Market Cap | $8.62B | $16.82B |
Volume | 2,594,626 | 223,093 |
Sector | Health | Health |
52-Week High | $87.26 | $630.19 |
52-Week Low | $54.76 | $393.42 |
Typical Hold Time | 19 Days | 14 Days |
Enterprise Value | $8.72B | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.91, up 2.93% with bearish technical signals despite strong analyst support. The company shows promising drug development with positive Phase 3 results for aficamten in HCM treatment, though fundamentals remain challenged with a P/S ratio of 114 and negative profit margins. Recent executive stock sales and high cash burn from operations highlight ongoing financial pressures despite growing revenue potential from new drug launches.
The outlook balances significant upside potential from analyst price targets averaging $112.60 against substantial execution risks. While clinical successes position CYTK for growth in cardiovascular treatments, persistent losses and high valuation metrics require careful risk assessment. The stock offers speculative growth opportunity but demands close monitoring of commercialization progress and path to profitability.
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
